Skip to main content
. 2020 Jul 28;11:3766. doi: 10.1038/s41467-020-17556-z

Fig. 2. Bone-marrow-derived cells are the major source of DPP4 inhibitor-mediated increases in sDPP4.

Fig. 2

Plasma DPP4 activity a and sDPP4 protein levels b were measured 9 weeks following bone marrow transplant (BMT) or control procedure in control mice (Dpp4EC+/+) and mice with hematopoietic- and endothelial-specific inactivation of DPP4 (Dpp4EC−/−) after 7 days of free access to normal drinking water or water containing sitagliptin. Data shown are mean ± SEM. n = 12 Dpp4EC+/+– BMT, 9 Dpp4EC+/++ BMT, 6 Dpp4EC−/− – BMT and 7 or 9 for Dpp4EC−/− + BMT with or without sitagliptin, respectively. *P < 0.05, **P < 0.01, ****P < 0.0001 vs. the indicated comparator. #P < 0.01–0.0001 vs. the respective non-sitagliptin-treated group. All data were analysed by one-way ANOVA. Source data are provided as a Source data file.